|Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade.|
|PMID: 21858106 Owner: NLM Status: MEDLINE|
|Medial degeneration is a key feature of aneurysm disease and aortic dissection. In a murine aneurysm model we investigated the structural and functional characteristics of aortic wall degeneration in adult fibulin-4 deficient mice and the potential therapeutic role of the angiotensin (Ang) II type 1 (AT(1)) receptor antagonist losartan in preventing aortic media degeneration. Adult mice with 2-fold (heterozygous Fibulin-4(+/R)) and 4-fold (homozygous Fibulin-4(R/R)) reduced expression of fibulin-4 displayed the histological features of cystic media degeneration as found in patients with aneurysm or dissection, including elastin fiber fragmentation, loss of smooth muscle cells, and deposition of ground substance in the extracellular matrix of the aortic media. The aortic contractile capacity, determined by isometric force measurements, was diminished, and was associated with dysregulation of contractile genes as shown by aortic transcriptome analysis. These structural and functional alterations were accompanied by upregulation of TGF-β signaling in aortas from fibulin-4 deficient mice, as identified by genome-scaled network analysis as well as by immunohistochemical staining for phosphorylated Smad2, an intracellular mediator of TGF-β. Tissue levels of Ang II, a regulator of TGF-β signaling, were increased. Prenatal treatment with the AT(1) receptor antagonist losartan, which blunts TGF-β signaling, prevented elastic fiber fragmentation in the aortic media of newborn Fibulin-4(R/R) mice. Postnatal losartan treatment reduced haemodynamic stress and improved lifespan of homozygous knockdown fibulin-4 animals, but did not affect aortic vessel wall structure. In conclusion, the AT(1) receptor blocker losartan can prevent aortic media degeneration in a non-Marfan syndrome aneurysm mouse model. In established aortic aneurysms, losartan does not affect aortic architecture, but does improve survival. These findings may extend the potential therapeutic application of inhibitors of the renin-angiotensin system to the preventive treatment of aneurysm disease.|
|Els Moltzer; Luuk te Riet; Sigrid M A Swagemakers; Paula M van Heijningen; Marcel Vermeij; Richard van Veghel; Angelique M Bouhuizen; Joep H M van Esch; Stephanie Lankhorst; Natasja W M Ramnath; Monique C de Waard; Dirk J Duncker; Peter J van der Spek; Ellen V Rouwet; A H Jan Danser; Jeroen Essers|
Related Documents :
|6722676 - Chronic traumatic aneurysm of the descending thoracic aorta with compression of the tra...
17210406 - Repair of recurrent visceral aortic patch aneurysm after thoracoabdominal aortic aneury...
11156056 - Anatomic exposures in thoracoabdominal aortic surgery.
12756346 - Inflammatory aneurysm in the infrarenal portion of thoracoabdominal aneurysms: an uncom...
8114186 - Natural history of atherosclerotic renal artery stenosis: a prospective study with dupl...
8372716 - In vivo flow visualization of induced saccular cerebral aneurysms in rats.
|Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2011-08-09|
|Title: PloS one Volume: 6 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2011|
|Created Date: 2011-08-22 Completed Date: 2012-02-15 Revised Date: 2013-06-27|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e23411 Citation Subset: IM|
|Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.|
|APA/MLA Format Download EndNote Download BibTex|
Angiotensin II Type 1 Receptor Blockers / pharmacology
Aorta, Thoracic / metabolism, pathology, physiopathology*
Aortic Aneurysm / genetics, physiopathology*, prevention & control
Extracellular Matrix Proteins / deficiency*, genetics
Losartan / pharmacology
Mice, 129 Strain
Mice, Inbred C57BL
Oligonucleotide Array Sequence Analysis
Phenylephrine / pharmacology
Receptor, Angiotensin, Type 1 / physiology
Smad2 Protein / genetics, metabolism
Transforming Growth Factor beta / genetics, metabolism
Vasoconstriction / drug effects, genetics, physiology*
Vasoconstrictor Agents / pharmacology
|0/Angiotensin II Type 1 Receptor Blockers; 0/Extracellular Matrix Proteins; 0/Receptor, Angiotensin, Type 1; 0/SMAD2 protein, human; 0/Smad2 Protein; 0/Transforming Growth Factor beta; 0/Vasoconstrictor Agents; 0/fibulin-4; 11128-99-7/Angiotensin II; 114798-26-4/Losartan; 59-42-7/Phenylephrine|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hox10 genes function in kidney development in the differentiation and integration of the cortical st...
Next Document: Identifying host genetic risk factors in the context of public health surveillance for invasive pneu...